Skip to main content

LCD L34580: Intravenous Immunoglobulin (IVIG)

LCD L34580, Intravenous Immunoglobulin (IVIG), is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2024-04-04 and first in force 2015-10-01. The policy text runs 374 words, and its billing and coding article A56718 lists 212 ICD-10-CM codes that support medical necessity for 13 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2024-04-04
Original effective
2015-10-01
Policy text
374 words
Covered ICD-10 codes (articles)
212

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L34580
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A56718: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56718 (Billing and Coding: Intravenous Immunoglobulin (IVIG)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A56718: Billing and Coding: Intravenous Immunoglobulin (IVIG) (Billing and Coding, effective 2026-07-01)

Covered ICD-10-CM codes
212
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
13
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56718
ICD-10-CMDescription (FY2027)
A85.8Other specified viral encephalitis
B08.3Erythema infectiosum [fifth disease]
B20Human immunodeficiency virus [HIV] disease
B25.0Cytomegaloviral pneumonitis
B25.1Cytomegaloviral hepatitis
B25.2Cytomegaloviral pancreatitis
B25.8Other cytomegaloviral diseases
B25.9Cytomegaloviral disease, unspecified
C88.00Waldenstrom macroglobulinemia not having achieved remission
C90.00Multiple myeloma not having achieved remission
C90.02Multiple myeloma in relapse
C91.10Chronic lymphocytic leukemia of B-cell type not having achieved remission
C91.11Chronic lymphocytic leukemia of B-cell type in remission
C91.12Chronic lymphocytic leukemia of B-cell type in relapse
D47.3Essential (hemorrhagic) thrombocythemia
D55.0Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency
D55.1Anemia due to other disorders of glutathione metabolism
D55.21Anemia due to pyruvate kinase deficiency
D55.29Anemia due to other disorders of glycolytic enzymes
D55.3Anemia due to disorders of nucleotide metabolism
D55.8Other anemias due to enzyme disorders
D55.9Anemia due to enzyme disorder, unspecified
D56.0Alpha thalassemia
D56.1Beta thalassemia

Procedure codes: J1459 (Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1552 (Injection, immune globulin (alyglo), 500 mg), J1554 (Injection, immune globulin (asceniv), 500 mg), J1556 (Injection, immune globulin (bivigam), 500 mg), J1557 (Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1561 (Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg), J1566 (Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg), J1568 (Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1569 (Injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg), J1576 (Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1599 (Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg), J2791 (Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu), J2792 (Injection, rho d immune globulin, intravenous, human, solvent detergent, 100 iu).

Coverage indications, limitations and medical necessity

Intravenous Immune Globulin (IVIG) is a solution of human immunoglobulins specifically prepared for intravenous infusion. Immunoglobulins contain a broad range of antibodies that act specifically against bacterial and viral antigens.

INDICATIONS:

• Treatment of primary immunodeficiency syndromes associated with defects in humoral immunity to replace or boost immunoglobulin G (IgG)

• Treatment of idiopathic thrombocytopenic purpura (ITP) when a rapid rise in the platelet count is required such as prior to surgery, to control excessive bleeding, or to defer or avoid splenectomy

• Treatment of Kawasaki disease, in conjunction with aspirin

• Prevention of recurrent bacterial infections in patients with hypogammaglobulinemia associated with B-cell chronic lymphocytic leukemia (CLL)

• Decreasing risk of acute graft versus host disease, associated interstitial pneumonia, and infections after bone marrow transplant in the first 100 days after transplantation

• Reducing the risk of severe bacterial infections in human immunodeficiency virus (HIV) infected children with a CD4 count of greater than 200 to 400

• Second-line treatment of certain autoimmune myopathies

• Treatment of adults with Guillain-Barr é syndrome diagnosed within the first 2 weeks of illness

• Treatment of hyperimmunoglobulinemia E syndrome and Lambert-Eaton myasthenic syndrome (LEMS)

• Treatment of multifocal motor neuropathy (MMN)

• Treatment of relapsing-remitting multiple sclerosis

• Treatment of chronic parvovirus B19 infection and severe anemia associated with bone marrow suppression and pure red cell aplasia

• Treatment of progressive pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa acquisita in patients that have failed conventional treatment and patients in whom conventional therapy is otherwise contraindicated

• For coverage criteria of autoimmune mucocutaneous blistering diseases, please see CMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations Manual, Chapter 1, Part 4, §250.3

• Treatment of stiff person syndrome

• Treatment of myasthenia gravis (MG) in patients who have profound, rapidly progressive and/or potentially life-threatening muscular weakness and are refractory to, or intolerant of cholinesterase inhibitors, corticosteroids and azathioprine

• Prevention and/or treatment of organ rejection in patients sensitized to living or cadaveric organ donors

• Schonlein-Henoch

• Treatment of paraneoplastic visual loss

• Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in patients meeting the necessary criteria

• Treatment of multiple myeloma for the prevention of life-threatening infections due to reduced gamma globulins

Summary of evidence (opening)

IVIG has been used for many years in the treatment of immunodeficiency disease. As the knowledge of these diseases has improved and expanded, the use of IVIG has proportionally grown. With this, the body of literature supporting the use of IVIG in these situations has equally grown. The literature supports the use of IVIG in acute situations such as prevention of infections in patients with solid organ and bone marrow transplants, myeloma, leukemia, and HIV infections as well as in the acquired and genetic immunodeficiency syndromes such as CIDP. Additionally, the use in blocking damage by toxic antibodies in Guillain-Barré syndrome, pemphigus and its variants has been shown to be effective.

The contractor cites 30 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2024-04-04
Last reviewed by the contractor
2024-02-27
MCD version
57
Derived from
L33761

The contractor lists one National Coverage Determination as related: NCD 250.3 Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A58289 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L34580 cover?

Intravenous Immune Globulin (IVIG) is a solution of human immunoglobulins specifically prepared for intravenous infusion. Immunoglobulins contain a broad range of antibodies that act specifically against bacterial and viral antigens. The full 374-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L34580 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L34580?

The companion billing and coding article A56718 lists 212 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L34580?

A denial under LCD L34580 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56718's 212 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.